{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T11:01:31Z","timestamp":1787482891485,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81400185"],"award-info":[{"award-number":["81400185"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800356"],"award-info":[{"award-number":["81800356"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800336"],"award-info":[{"award-number":["81800336"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genet"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12881-018-0734-2","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T19:25:41Z","timestamp":1545852341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease"],"prefix":"10.1186","volume":"19","author":[{"given":"Chi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2598-2576","authenticated-orcid":false,"given":"Qiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,27]]},"reference":[{"key":"734_CR1","doi-asserted-by":"crossref","unstructured":"Fabry J. Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura haemorrhagica Hebrae). Arch Dermatol Syph. 1898;43(1):187\u2013200.","DOI":"10.1007\/BF01986897"},{"key":"734_CR2","doi-asserted-by":"crossref","unstructured":"Anderson W. A case of angiokeratoma. Br J Dermatol. 1898;10:113\u20137.","DOI":"10.1111\/j.1365-2133.1898.tb16317.x"},{"issue":"2","key":"734_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","volume":"337","author":"SC Garman","year":"2004","unstructured":"Garman SC, Garboczi DN. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol. 2004;337(2):319\u201335.","journal-title":"J Mol Biol"},{"issue":"4","key":"734_CR4","first-page":"316","volume":"52","author":"A Anastasakis","year":"2011","unstructured":"Anastasakis A, Sevdalis E, Papatheodorou E, Stefanadis C. Anderson-Fabry disease: a cardiomyopathy that can be cured. Hellenic J Cardiol. 2011;52(4):316\u201326.","journal-title":"Hellenic J Cardiol"},{"issue":"6","key":"734_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1399-0004.2011.01718.x","volume":"81","author":"O Lidove","year":"2012","unstructured":"Lidove O, Kaminsky P, Hachulla E, Leguy-Seguin V, Lavigne C, Marie I, Maillot F, Serratrice C, Masseau A, Cherin P, et al. Fabry disease 'The new great Imposter': results of the French Observatoire in Internal Medicine Departments (FIMeD). Clin Genet. 2012;81(6):571\u20137.","journal-title":"Clin Genet"},{"issue":"5","key":"734_CR6","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jpeds.2010.02.012","volume":"156","author":"CL Marchesoni","year":"2010","unstructured":"Marchesoni CL, Roa N, Pardal AM, Neumann P, Caceres G, Martinez P, Kisinovsky I, Bianchi S, Tarabuso AL, Reisin RC. Misdiagnosis in Fabry disease. J Pediatr. 2010;156(5):828\u201331.","journal-title":"J Pediatr"},{"issue":"5","key":"734_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/WCO.0b013e32834a9433","volume":"24","author":"K Toyooka","year":"2011","unstructured":"Toyooka K. Fabry disease. Curr Opin Neurol. 2011;24(5):463\u20138.","journal-title":"Curr Opin Neurol"},{"issue":"Suppl 1","key":"734_CR8","first-page":"88","volume":"12","author":"AS Thomas","year":"2014","unstructured":"Thomas AS, Hughes DA. Fabry disease. Pediatr Endocrinol Rev. 2014;12(Suppl 1):88\u2013101.","journal-title":"Pediatr Endocrinol Rev"},{"key":"734_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"734_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.gene.2013.09.058","volume":"535","author":"G Duro","year":"2014","unstructured":"Duro G, Musumeci MB, Colomba P, Zizzo C, Albeggiani G, Mastromarino V, Volpe M, Autore C. Novel alpha-galactosidase a mutation in patients with severe cardiac manifestations of Fabry disease. Gene. 2014;535(2):365\u20139.","journal-title":"Gene"},{"issue":"2 Pt 1","key":"734_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.gene.2015.09.088","volume":"575","author":"H Peng","year":"2016","unstructured":"Peng H, Xu X, Zhang L, Zhang X, Peng H, Zheng Y, Luo S, Guo H, Xia K, Li J, et al. GLA variation p.E66Q identified as the genetic etiology of Fabry disease using exome sequencing. Gene. 2016;575(2 Pt 1):363\u20137.","journal-title":"Gene"},{"issue":"21","key":"734_CR12","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. Jama. 2001;285(21):2743\u20139.","journal-title":"Jama"},{"issue":"1","key":"734_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ, International collaborative Fabry disease study G. Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry's disease. N Engl J Med. 2001;345(1):9\u201316.","journal-title":"N Engl J Med"},{"issue":"7","key":"734_CR14","doi-asserted-by":"publisher","first-page":"A762","DOI":"10.1016\/j.jval.2015.09.2494","volume":"18","author":"R Parini","year":"2015","unstructured":"Parini R, Schiffmann R, Fotheringham I, Todorova L. A systematic review of the humanistic burden of disease in patients with Fabry disease. Value Health. 2015;18(7):A762.","journal-title":"Value Health"},{"issue":"1","key":"734_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","volume":"29","author":"RJ Kalliokoski","year":"2006","unstructured":"Kalliokoski RJ, Kantola I, Kalliokoski KK, Engblom E, Sundell J, Hannukainen JC, Janatuinen T, Raitakari OT, Knuuti J, Penttinen M, et al. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis. 2006;29(1):112\u20138.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"734_CR16","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s10545-008-0848-3","volume":"31","author":"JW Koskenvuo","year":"2008","unstructured":"Koskenvuo JW, Hartiala JJ, Nuutila P, Kalliokoski R, Viikari JS, Engblom E, Penttinen M, Knuuti J, Mononen I, Kantola IM. Twenty-four-month alpha-galactosidase a replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab Dis. 2008;31(3):432\u201341.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"734_CR17","first-page":"216","volume":"52","author":"A Mursa","year":"2014","unstructured":"Mursa A, Ginghina C, Jurcut R. Fabry disease--a primer for cardiologists. Rom J Intern Med. 2014;52(4):216\u201322.","journal-title":"Rom J Intern Med"},{"issue":"8","key":"734_CR18","doi-asserted-by":"publisher","first-page":"e1003632","DOI":"10.1371\/journal.pgen.1003632","volume":"9","author":"J Lukas","year":"2013","unstructured":"Lukas J, Giese AK, Markoff A, Grittner U, Kolodny E, Mascher H, Lackner KJ, Meyer W, Wree P, Saviouk V, et al. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet. 2013;9(8):e1003632.","journal-title":"PLoS Genet"},{"issue":"1","key":"734_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/humu.22910","volume":"37","author":"J Lukas","year":"2016","unstructured":"Lukas J, Scalia S, Eichler S, Pockrandt AM, Dehn N, Cozma C, Giese AK, Rolfs A. Functional and clinical consequences of novel alpha-galactosidase a mutations in Fabry disease. Hum Mutat. 2016;37(1):43\u201351.","journal-title":"Hum Mutat"},{"issue":"3","key":"734_CR20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","volume":"64","author":"S Nakao","year":"2003","unstructured":"Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \"renal variant\" phenotype. Kidney Int. 2003;64(3):801\u20137.","journal-title":"Kidney Int"},{"issue":"4","key":"734_CR21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","volume":"119","author":"F Weidemann","year":"2009","unstructured":"Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S, Voelker W, Ertl G, Wanner C, Strotmann J. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009;119(4):524\u20139.","journal-title":"Circulation"},{"issue":"3","key":"734_CR22","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","volume":"27","author":"DG Warnock","year":"2012","unstructured":"Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, Marodi L, Mignani R, Vujkovac B, Beitner-Johnson D, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. 2012;27(3):1042\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"734_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","volume":"105","author":"WR Wilcox","year":"2012","unstructured":"Wilcox WR, Linthorst GE, Germain DP, Feldt-Rasmussen U, Waldek S, Richards SM, Beitner-Johnson D, Cizmarik M, Cole JA, Kingma W, et al. Anti-alpha-galactosidase a antibody response to agalsidase beta treatment: data from the Fabry registry. Mol Genet Metab. 2012;105(3):443\u20139.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"734_CR24","doi-asserted-by":"publisher","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","volume":"2","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, Aerts JM, Hirth A, Hollak CE. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg. PLoS One. 2007;2(7):e598.","journal-title":"PLoS One"},{"issue":"1","key":"734_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2183\/pjab.88.18","volume":"88","author":"S Ishii","year":"2012","unstructured":"Ishii S. Pharmacological chaperone therapy for Fabry disease. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(1):18\u201330.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"1","key":"734_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/4801","volume":"5","author":"JQ Fan","year":"1999","unstructured":"Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase a in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999;5(1):112\u20135.","journal-title":"Nat Med"},{"issue":"4","key":"734_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, Vockley G, Hamazaki T, Lachmann R, Ohashi T, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288\u201396.","journal-title":"J Med Genet"},{"issue":"4","key":"734_CR28","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, Bronfin B, Williams H, Yu J, Bichet DG, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19(4):430\u20138.","journal-title":"Genet Med"},{"issue":"6","key":"734_CR29","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, et al. Treatment of Fabry's disease with the pharmacologic chaperone Migalastat. N Engl J Med. 2016;375(6):545\u201355.","journal-title":"N Engl J Med"},{"issue":"3","key":"734_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s40259-013-0032-7","volume":"27","author":"AP Ruiz de Garibay","year":"2013","unstructured":"Ruiz de Garibay AP, Solinis MA, Rodriguez-Gascon A. Gene therapy for fabry disease: a review of the literature. BioDrugs. 2013;27(3):237\u201346.","journal-title":"BioDrugs"},{"issue":"2","key":"734_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1042\/BJ20070479","volume":"406","author":"S Ishii","year":"2007","unstructured":"Ishii S, Chang HH, Kawasaki K, Yasuda K, Wu HL, Garman SC, Fan JQ. Mutant alpha-galactosidase a enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. The Biochemical journal. 2007;406(2):285\u201395.","journal-title":"The Biochemical journal"},{"issue":"34","key":"734_CR32","doi-asserted-by":"publisher","first-page":"28386","DOI":"10.1074\/jbc.M112.351056","volume":"287","author":"A Siekierska","year":"2012","unstructured":"Siekierska A, De Baets G, Reumers J, Gallardo R, Rudyak S, Broersen K, Couceiro J, Van Durme J, Schymkowitz J, Rousseau F. Alpha-galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants. J Biol Chem. 2012;287(34):28386\u201397.","journal-title":"J Biol Chem"}],"container-title":["BMC Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12881-018-0734-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12881-018-0734-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12881-018-0734-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T19:17:26Z","timestamp":1577387846000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenet.biomedcentral.com\/articles\/10.1186\/s12881-018-0734-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["734"],"URL":"https:\/\/doi.org\/10.1186\/s12881-018-0734-2","relation":{},"ISSN":["1471-2350"],"issn-type":[{"value":"1471-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"24 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written information consent for participation and publication were obtained from all the individuals which are described in this manuscript. The parents provided consent in the case of children under 16. The present study was approved by the Medical Ethics Committee of Tongji Hospital, Tongji Medical Collage, Huazhong University of Science and Technology, and complied with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient in Fig. a consented to the inclusion of his picture in this manuscript in written format.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"219"}}